Articles and whitepapers related to the PEVIVA products


Showing 616 of filtered documents

Patient-derived lung cancer “sandwich cultures” with preserved tumor microenvironment

H Wang, T Walles, C Wiese-Rischke

Tissue Engineering; 2023

Drinking and laboratory biomarkers, and nutritional status characterize the clinical presentation of early-stage alcohol-associated liver disease

V Vatsalya, AJ Royer, SK Jha, R Parthasarathy, H Tiwari, W Feng, VA Ramchandani, IA Kirpich, CJ McClain

Advances in Clinical Chemistry; 2023:83-108

Dynamic Changes of the Fungal Microbiome in Alcohol Use Disorder

P Hartmann, S Lang, S Zeng, Y Duan, X Zhang, Y Wang, M Bondareva, A Kruglov, D E Fouts, P Stärkel, B Schnabl

Frontiers in Physiology; 2021

Liver Injury and Endotoxemia in Male and Female Alcohol-Dependent Individuals Admitted to an Alcohol Treatment Program

IA Kirpich, C J McClain, V Vatsalya, M Schwandt, M Phillips, K C Falkner, L Zhang, C Harwell, D T George, J C Umhau

Alcoholism, clinical and experimental research; 2017:747-757

Advances in Noninvasive Biomarkers for Nonalcoholic Fatty Liver Disease

GE Gîlc?-Blanariu, D S Budur, D E Mitric?, E Gologan, O Timofte, G G B?lan, V A Olteanu, G ?tef?nescu

Metabolites; 2023:1115

Safety and pharmacokinetics of BI 685509, a soluble guanylyl cyclase activator, in patients with cirrhosis: A randomized Phase Ib study

EJ Lawitz, T Reiberger, J M Schattenberg, C Schoelch, H O Coxson, D Wong, J Ertle

Hepatology Communications; 2023

Impact of obesity on liver function tests: is nonalcoholic fatty liver disease the only player? A review article

MM El-Eshmawy

Porto Biomedical Journal; 2023

Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial

SA Harrison, R Taub, G W Neff, K J Lucas, D Labriola, SE Moussa, N Alkhouri, M R Bashir

Nature Medicine; 2023:2919-2928